PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND ITS CORRELATION WITH METABOLIC SYNDROME

Mariana Drechmer ROMANOWSKI, Monica Beatriz PAROLIN, Alexandre C T FREITAS, Mauri J PIAZZA, Jorgete BASSO and Almir A URBANETZ

ABSTRACT - Background: The polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women at childbearing age. Metabolic syndrome is present from 28% to 46% of patients with PCOS. Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic expression of metabolic syndrome. There are few published studies that correlate PCOS and NAFLD.

Objective: To determine the prevalence of NAFLD and metabolic syndrome in patients with PCOS, and to verify if there is a correlation between NAFLD and metabolic syndrome in this population.

Methods: Study developed at Gynecology Department of Clinical Hospital of Federal University of Parana (UFPR). The sessions were conducted from April 2008 to January 2009. One hundred and thirty-one patients joined the analysis; 101 were diagnosed with PCOS and 30 formed the control group. We subdivided the PCOS patients into two subgroups: PCOS+NAFLD and PCOS. All the patients were submitted to hepatic sonography. For hepatoecholosus screening, hepatic ecotexture was compared to spleen's. For diagnosis of metabolic syndrome, we adopted the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) criteria, as well as the criteria proposed by International Diabetes Federation. Statistical analysis were performed with t of student and U of Mann-Whitney test for means and chi square for proportions.

Results: At PCOS group, NAFLD was present in 23.8% of the population. At control group, it represented 3.3%, with statistical significance (P=0.01). Metabolic syndrome, by NCEP/ATP III criteria, was diagnosed in 32.7% of the women with PCOS and in 26.6% of the women at control group (no statistical difference, P=0.5). At PCOS+DHGNA subgroup, age, weight, BMI, abdominal circumference and glucose tolerance test results were higher when compared to PCOS group (P<0.01). Metabolic syndrome by NCEP/ATPIII criteria was present in 75% and by International Diabetes Federation criteria in 95.8% of women with PCOS+NAFLD with P<0.01. Insulin levels at SOP+DHGNA were higher than at PCOS group with P<0.01.

Conclusion: Almost 25% of the patients with PCOS were diagnosed for NAFLD. Metabolic syndrome was present between 32.7% and 44.6% of patients with PCOS. At subgroup PCOS+NAFLD, metabolic syndrome is highly prevalent. These patients are more obese, with higher BMI and higher glucose levels.

HEADINGS - Polycystic ovary syndrome. Fatty liver. Metabolic syndrome X.

INTRODUCTION

The polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting from 5% to 11% of women at childbearing age(1,2,3,9,10). The classical PCOS is characterized by irregular menstrual cycles (oligomenorrhea) and evidence of clinical and/or laboratorial hyperandrogenism with hirsutism, acne, androgenic pattern of alopecia and ultrasound findings of polycystic ovaries, in the absence of other medical conditions coursing with androgen excess (hyperprolactinemia, non classical congenital adrenal hyperplasia, Cushing syndrome, androgen-producing neoplasm and acromegaly).

Although in its most typical form PCOS course with hyperandrogenism and chronic anovulation, diagnostic criteria recently proposed(11,12) consider that PCOS can be found in patients with ovulatory cycles but having hyperandrogenism (clinical or biological) and polycystic ovaries(11,12) and in patients with chronic anovulation, polycystic ovaries but without excess of androgens(12), as it is observed in Figure 1.
The association of PCOS with insulin resistance state, resulting in effects on reproductive, metabolic and cardiovascular health of affected patients, rekindled interest of the scientific community about this endocrine condition since it identifies a subgroup of individuals who deserves a broader and deeper approach than just the treatment of the most common events as hirsutism, acne and oligomenorrhea.

Insulin plays direct and indirect roles in the pathogenesis of hyperandrogenism in women with PCOS. It acts synergistically with the luteinizing hormone (LH) increasing the androgen synthesis by ovarian theca cells. In addition, insulin inhibits the steroid hormone binding globulin (SHBG) synthesis by the liver, increasing the amount of free and biologically active testosterone in the circulation. Since patients with PCOS usually have hyperinsulinemia, the concentration of free testosterone is increased even if the total amount of testosterone is within the upper limit of normality or moderately elevated.

Because insulin resistance is one of the pathophysiologic bases of metabolic syndrome, patients with PCOS and high levels of plasmatic insulin have a substantial risk of developing metabolic and cardiovascular complications such as obesity, glucose intolerance and type 2 diabetes, dyslipidemia, and coronary heart disease. In fact, several studies point to a higher frequency of metabolic syndrome (MS) or some of its components alone in women with PCOS when compared to the normal population. Marcondes et al. published a retrospective study on the MS prevalence in women with PCOS who were followed at Hospital de Clínicas at University of São Paulo, which found high levels (about 38%), when the modified criteria of NCET ATP III recommended by ESHRE/ASRM-PCOS, Consensus Workshop Group is applied.

In fact, the current approach of patients with PCOS should necessarily include screening for MS risk factors. The American College of Cardiology recommends that women with PCOS should be evaluated for possible metabolic disorders, including performing fasting and 2 hours postprandial glucose (Oral Glucose Tolerance Test or OGTT), basal insulin levels, glycosylated hemoglobin and lipids levels. OGTT is the most sensitive method to detect glucose intolerance in women with PCOS.

Similar as happens in PCOS and MS, insulin resistance also emerges on the pathogenesis basis of non-alcoholic fatty liver disease (NAFLD), the most common form of liver disease nowadays. Thus, insulin resistant patients have a greater risk of developing NAFLD. Due to the evolutionary potential of NAFLD, particularly in individuals with metabolic syndrome, early diagnostic and therapeutic intervention are of great value for such patients.

The gold standard for the diagnosis of NAFLD is liver biopsy, but this method presents some limitations such as sampling variability (heterogeneous parenchymal involvement), higher cost and complication risks because it is an invasive procedure. Liver function tests (serum samples) may show up within normal limits or have a fluctuating course in NAFLD patients. In fact, severe forms of NAFLD have already been described in patients with normal enzymes. Imaging methods such as ultrasound can detect the presence of steatosis but without quantifying the degree of inflammatory activity or evaluate the level of eventual fibrosis. The ultrasound lacks sensitivity in cases in which the amounts of fat deposited are under 30%. But, because it is a faster, cheaper and non-invasive method, ultrasound has been used in many epidemiological studies and also in medical practice. Magnetic resonance imaging (MRI), even though more sensitive in detection and quantification of steatosis, is quite more expensive, what restricts its applicability as a screening test.

Deepest knowledge of PCOS pathophysiology shows its systemic repercussions, associated to considerable morbidity, what requires special attention from the medical team and multidisciplinary approach. Although metabolic evaluation of these patients is already a routine, compilation of such data will be valuable to profile the metabolic complications of PCOS in Brazilian women, whose genetic background and life habits are distinct from the population already studied.

METHODS

Prospective study was conducted to determine the prevalence of NAFLD and MS in adult women with PCOS. Patients came from the Endocrine Gynecology Clinic at Clínicas Hospital at UFPR. Sessions were conducted from April 2008 to January 2009 and during this period 137 patients were included in the study, among women with PCOS (n=103) and controls (n=34). Study design was approved by the Department of Gynecology of Clínicas Hospital at UFPR and by the Ethic Committee in Research in Humans at the same institution.
Inclusion criteria

Women aged ≥18 years old with confirmed diagnosis of PCOS based on criteria established by the Androgen Excess Society Guidelines(12), not using hormonal contraception for at least 3 months, were included. Patients who met at least one of the following criteria were excluded:

a) previous history of chronic liver disease;

b) suffering from conditions that can occur with known liver enzyme abnormalities;

c) using medication that are risk factors for NAFLD such as corticosteroids, tamoxifen, amiodarone, diltiazem, protease inhibitors (ARVs);

d) using metformin for hirsutism because it may interfere in blood glucose levels;

e) daily consumption of ethanol ≥20 grams;

f) failure to agree in participating in the study.

Control group was formed by women that spontaneously looked for medical care with symptoms of irregular menstrual cycles, infertility, hirsutism, acne, or problems trying to lose weight, but did not have the criteria for PCOS.

Protocol

All included patients were submitted to anamnesis and physical examination to collect the following variables (see data collection sheet):

a) age, menstrual pattern, a history of arterial hypertension treatment, family history of diabetes treatment, history of dyslipidemia treatment;

b) race, weight, height (cm), waist circumference (cm), presence of acne, hirsutism, androgenic alopecia, acanthosis nigricans (indirect sign of insulin resistance) and systemic arterial pressure in the supine position (after 20 minutes of rest).

Regarding the already established PCOS diagnosis, follow- ing data were collected from medical records: pattern of menstrual cycles; ultrasonographic findings in ovaries; testosterone serum level; free androgen; dehydroepiandrosterone sulfate level; evidence of exclusion of other causes of menstrual cycles irregularities or excess of androgen including hyperprolactinemia, non-controlled thyroid disease, congenital adrenal hyperplasia, premature ovarian failure, Cushing’s syndrome, androgen-secreting tumor or pregnancy.

After the interview, the patients were requested to take a sonogram of the right hypochondrium with one of the researchers (all the sonograms were conducted by researcher Basso), and to collect the following laboratory exams after an overnight fast (12 hours of fasting):

- Fasting glucose (≥100 mg/dL) and for the waist circumference >88 cm;
- Fasting glucose ≥110 mg/dL or - Glucose 2 hours after overload ≥140 mg/dL (oral glucose tolerance test);
- Fasting triglycerides ≥150 mg/dL;
- HDL cholesterol <50 mg/dL;
- Blood pressure ≥130/85 mmHg.

For the diagnosis of MS, the following criteria were used:

a) Criteria proposed by the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) and adapted for use in patients with PCOS by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop(20). Presence of at least 3 of the criteria below:

- Waist circumference >88 cm;
- Fasting glucose ≥110 mg/dL or - Glucose 2 hours after overload ≥140 mg/dL (oral glucose tolerance test);
- Fasting triglycerides ≥150 mg/dL;
- HDL cholesterol <50 mg/dL;
- Blood pressure ≥130/85 mmHg.

b) Criteria proposed by the International Diabetes Federation (IDF)(23–27), which reduce threshold values for fasting glucose (≥100 mg/dL) and for the waist circumference (>80 cm for Asian and South American women) associated with the proposal by the American Heart Association/National Heart, Lung, and Blood Institute Criteria for Diagnosis of the Metabolic Syndrome(21), where the criterion of hypertension is achieved by the presence of systolic BP ≥130 and/or diastolic BP ≥80 mmHg, and the triglycerides, HDL-c and PA are considered abnormal in patients who are on medication to control these factors. Presence of at least three of the criteria below:

- Waist circumference >80 cm;
- Fasting glucose ≥100 mg/dL or on treatment for hyperglycemia;
- Fasting triglycerides ≥150 mg/dL or on treatment for hypertriglyceridemia;
- HDL cholesterol <50 mg/dL or on treatment for reduced HDL-c;
- Systolic blood pressure ≥130 mmHg and/or diastolic ≥85 mmHg or history of hypertension and in use of antihypertensive;

Ultrasound diagnosis of NAFLD

All patients were submitted to ultrasonography of the liver with 3.5 MHz convex transducer. For the screening for hepatic steatosis, hepatic parenchymal echo texture was evaluated and compared with the echo texture of the spleen. When isoechogenic, the liver parenchyma is considered normal, that is, without evidence of steatosis. The presence of hyperechoic hepatic parenchyma (bright liver) is considered a characteristic of hepatic steatosis(20). The presence of steatosis was classified in:

HOMA-IR method was used to determine insulin resistance. It is calculated according to the formula below (22).

\[
\text{HOMA-IR} = \frac{\text{glucose fasting (mg/dL)} \times \text{basal insulin (\muUI/mL)}}{405}
\]

For diagnosis of MS, the following criteria were used:

a) Criteria proposed by the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) and adapted for use in patients with PCOS by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop(20). Presence of at least three of the criteria below:

- Waist circumference ≥88 cm;
- Fasting glucose ≥110 mg/dL or - Glucose 2 hours after overload ≥140 mg/dL (oral glucose tolerance test);
- Fasting triglycerides ≥150 mg/dL;
- HDL cholesterol <50 mg/dL;
- Blood pressure ≥130/85 mmHg.

b) Criteria proposed by the International Diabetes Federation (IDF)(23–27), which reduce threshold values for fasting glucose (≥100 mg/dL) and for the waist circumference (≥80 cm for Asian and South American women associated with the proposal by the American Heart Association/National Heart, Lung, and Blood Institute Criteria for Diagnosis of the Metabolic Syndrome(21), where the criterion of hypertension is achieved by the presence of systolic BP ≥130 and/or diastolic BP ≥80 mmHg, and the triglycerides, HDL-c and PA are considered abnormal in patients who are on medication to control these factors. Presence of at least three of the criteria below:

- Waist circumference ≥80 cm;
- Fasting glucose ≥100 mg/dL or on treatment for hyperglycemia;
- Fasting triglycerides ≥150 mg/dL or on treatment for hypertriglyceridemia;
- HDL cholesterol <50 mg/dL or on treatment for reduced HDL-c;
- Systolic blood pressure ≥130 mmHg and/or diastolic ≥85 mmHg or history of hypertension and in use of antihypertensive;

Ultrasound diagnosis of NAFLD

All patients were submitted to ultrasonography of the liver with 3.5 MHz convex transducer. For the screening for hepatic steatosis, hepatic parenchymal echo texture was evaluated and compared with the echo texture of the spleen. When isoechogenic, the liver parenchyma is considered normal, that is, without evidence of steatosis. The presence of hyperechoic hepatic parenchyma (bright liver) is considered a characteristic of hepatic steatosis(20). The presence of steatosis was classified in:
- Level I (mild) when there is a diffuse increase of fine echoes in the liver parenchyma but allows good view of the vessel walls;
- Level II (moderate) when diffuse increase of the echogenicity liver parenchyma difficult the view of the vascular walls and diaphragm;
- Level III (severe) when there is a significant increase of the fine echoes and intense posterior attenuation preventing the view of the vascular walls and diaphragm.

RESULTS

Two hundred and nine women attended the Gynecology outpatient at HC/UFPR for screening of PCOS, MS and NAFLD. Of these, 101 were diagnosed with PCOS, 30 had other diagnoses, such as premature ovarian failure and hyperthyroidism, 2 only presented clinical hyperandrogenism, without other criteria for PCOS. Seventy-six women were excluded from the study because they were outside the age range provided in the methods (n=2), because pregnancy was diagnosed (n=4), because they were using hormonal contraception and have not quit to enable the laboratory assays (n=25), or because they quit attendance to the meetings (n=45). These results are seen in Figure 2.

The patients were first divided into PCOS group and control group. These groups were compared in various criteria as shown on Table 1. It is observed that patients with PCOS, even younger than the patients from the control group.
group, showed higher weight, higher BMI and greater waist circumference. Patients with PCOS showed worse levels of HDL when compared with the control group. Moreover, as higher levels of insulin were showed, patients from the first group had a higher HOMA index than the second group. Regarding the prevalence of the MS diagnosis (NCEP/ATP III and IDF criteria), there was no difference between the analyzed groups.

PCOS and control groups were also compared in regard to the NAFLD prevalence (Table 2). PCOS group were diagnosed with NAFLD by ultrasonography in 23.8% of the patients, which is significantly higher than the prevalence of 3.3% in the control group.

Finally, patients with PCOS were divided into other two groups: PCOS with NAFLD and isolated PCOS. The groups were compared according to the same clinical and laboratorial criteria from Table 1. In this case, Table 3 shows that patients with NAFLD are older than the second group, in addition to having greater severity in almost all criteria defined for MS. They have greater weight, BMI, waist circumference, higher OGTT blood glucose, higher levels of triglycerides and a more severe hyperinsulinemia. Thus, it is understood why these patients showed higher HOMA index and higher prevalence of PCOS, regardless of the used criteria, when compared to patients without liver disease.

**DISCUSSION**

Published studies regarding the association between PCOS and NAFLD are still very scarce and recent and they evaluate populations with lifestyle and genetic background different from the Brazilian population (7). One of these studies applied PCOS diagnostic criteria in 14 women with NAFLD, finding a prevalence of 71% in this population (25).

In agreement with the literature, our results correlate the metabolic syndrome with the polycystic ovary syndrome. It is seen that patients with PCOS, although not

---

**TABLE 2.** Comparison of the prevalence of non-alcoholic fatty liver disease between patients with polycystic ovary syndrome group and control group

|                  | PCOS group (n=101) | Control group (n=30) | P    |
|------------------|--------------------|----------------------|------|
| NAFLD Present n (%) | 24 (23.8%)         | 1 (3.3%)             | 0.01 |
| NAFLD Absent n (%)  | 77 (76.2%)         | 28 (96.7%)           |      |

NAFLD: non-alcoholic fatty liver disease; PCOS group: polycystic ovary syndrome group.

**TABLE 3.** Comparison between patients with polycystic ovary syndrome and non-alcoholic fatty liver disease sub-group with patients only with polycystic ovary syndrome sub-group

| Sub-group PCOS+NAFLD (n=24) | Sub-group PCOS (n=77) | P  |
|-------------------------------|-----------------------|----|
| Age (years) ± DP              | 28.6 ± 5              | 26.2 ± 5 | 0.03 |
| Weight (kg) ± DP              | 89.3 ± 18             | 69.8 ± 18 | <0.01 |
| BMI (kg/m²) ± DP              | 34.2 ± 5              | 26.7 ± 5 | <0.01 |
| Waist circumference (cm) ± DP | 106.7 ± 12            | 86.9 ± 14 | <0.01 |
| Oral glucose tolerance test   |                       |                  |
| Fasting glucose (mg/dL) ± DP  | 100.6 ± 7             | 86.9 ± 7 | <0.01 |
| Blood glucose after 2 hours (mg/dL) ± DP | 121.9 ± 27 | 106.1 ± 27 | <0.01 |
| Area under the curve OGTT     | 1446.7 ± 200          | 1301.4 ± 211 | <0.01 |
| Triglycerides (mg/dL) ± DP    | 155.5 ± 83            | 87 ± 40 | <0.01 |
| HDL (mg/dL) ± DP              | 41.7 ± 8              | 46.8 ± 11 | 0.06 |
| SBP (mmHg) ± DP               | 118.2 ± 13            | 115.3 ± 13 | 0.2 |
| DBP (mmHg) ± DP               | 76.2 ± 12             | 74.5 ± 12 | 0.4 |
| MAP (mmHg) ± DP               | 141.3 ± 16            | 125.9 ± 13 | <0.01 |
| Insulin (µUI/mL) ± DP         | 18.5 ± 10             | 10.3 ± 9 | <0.01 |
| HOMA ± DP                     | 4.6 ± 2               | 2.4 ± 2 | <0.01 |
| Metabolic syndrome (NCEP/ATP III criterion) | | |
| Present n(%)                  | 75%                   | 19.5%       | <0.01 |
| Absent n(%)                   | 25%                   | 80.5%       | |
| Metabolic syndrome (IDF criterion) | | |
| Present (%)                   | 95.8%                 | 28.6%       | <0.01 |
| Absent n(%)                   | 4.2%                  | 71.4%       | |

PCOS+NAFLD sub-group: patients with non-alcoholic fatty liver disease sub-group associated to the polycystic ovary syndrome; PCOS sub-group: patients only with polycystic ovary syndrome sub-group; PD: pattern deviation; BMI: body mass index; OGTT: oral glucose tolerance test; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; NCEP/ATP III: National Cholesterol Education Program/Adult Treatment Panel III; IDF: International Diabetes Association.

---

v. 52 no. 2 - abr./jun. 2015 Arq Gastroenterol 121
presenting a higher MS incidence, have hyperinsulinemia, overweight, increase of the waist circumference and already start to present lipoprotein alterations. Insulin resistance is a common pathogenic mechanism of these two entities, and so it is expected that these women, if not monitored and treated, can develop MS, and even NAFLD, in the future.

Once the patients have NAFLD, the worst scores in virtually all the MS defining criteria are expected. However, it should be remembered that NAFLD itself is already a cardiovascular risk factor alone, and the assistant physician should not, thus, wait changes in glucose or lipids levels to begin treatment.

It is expected that the physician, especially, the gynecologist, watches not only for the reproductive and esthetic effects, but especially for the metabolic and liver consequences of PCOS.

Further studies to answer if it is valid to monitor all patients with PCOS for non-alcoholic fatty liver disease would be important for future references.

Authors’ contributions

Romanowski MD: data collection and writing of text. Parolin MB: writing of text, hepatology consultant. Freitas ACT: statistical analysis. Piazza MJ: writing of text. Basso J: ultrasound operator. Urbanetz AA: data collection, writing of text, supervision.
REFERENCES

1. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929-35.

2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al. Positional statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45.

3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.

4. Byasheva A, Legro RS, Dunaif A, Urbaneck M. Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrin Metab 2009;94(7):2617-25.

5. Brzozowska MM, Ostapowicz G, Weltman, MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009;24(2):243-7.

6. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412-7.

7. Charachezorowithaya P, Linder KD. Role of Radiologic Modalities in the Management of Non-alcoholic Steatohepatitis. Clin Liver Dis 2007;11(1):37-54.

8. Dokras A, Bochner M, Hollinrake E, Marklam S, VanVoorhis B, Jagasia DH, et al. Prevalence and predictors of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 1999;84(1):1-17.

9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-6.

10. Ehrmann DA, Barnes RB, Rosenfeld RI, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(3):141-6.

11. Franks S. Polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496-501.

12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005;112(17):2735-52.

13. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.

14. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots FR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1999;84(1):163-9.

15. Legro RS, Kunsman AR, Dodson WC, Dunai A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):163-9.

16. Marchesini G, Marzocchi R. Metabolic syndrome and NAFLD. Clin Liver Dis. 2007;11(1):105-17.

17. Marcondes JAM, Hayashida SAY, Barcellos CRG, Rocha MP, Maciel GAR, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metab. 2007;51(6):972-9.

18. Sturis J, Hunt AE, Steinberg HO, Paradisi G, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metabol. 2001;86(11):5456-464.

19. Oluwadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol. 2008;61(6):697-706.

20. Ong JP, Younouss ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16.

21. Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009;36(1):129-52.

22. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

23. Sejti TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2007;91(5):1741-7.

24. Srikanthan P, Korenman S, Davis S. Polycystic ovarian syndrome: the next cardiovascular dilemma in women? Endocrinol Metab Clin North Am. 2006;35(3):611-31.

25. The IDF consensus worldwide definition of metabolic syndrome. Available from: http://www.idf.org.

26. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Received 5/11/2014
Accepted 1/12/2014

v. 52 no. 2 - abr./jun. 2015
Arq Gastroenterol 123